The Beijing-based company said last month that it will use the funding to market its Shurui single-port surgical robot both domestically and internationally, as well as to accelerate the production of its next-generation products.
Single-port surgery is a minimally invasive approach involving endoscope and surgical instruments through a single incision. Surgerii said its Shurui robot uses snake-like instruments and teleoperation technology to assist clinicians in achieving precise operations.
Surgerii develops, produces, and commercializes laparoscopic surgical robotic systems and accessories. In September 2025, it obtained CE approval in Europe for Shurui. The company claimed that it was the second such approval after Intuitive Surgical received a CE mark for its da Vinci SP system in 2024.
Surgerii touts surgical innovations
The Shurui single-port endoscopic surgical system, or SR-ENS-600, is “the world’s first commercially available single-port surgical robot with snake-like instruments,” claimed Surgerii Robotics. The company noted that it has been building its intellectual property (IP) portfolio.
The core technology of the Shurui SP robot is based on the “Dual Continuum Mechanism” design developed by Prof. Kai Xu of Shanghai Jiao Tong University. Surgerii said the innovation enabled the development of its flexible instruments, which can perform highly complex and precise procedures through a single 1.8 cm (0.7 in.) incision.
During its financing round, investors systematically reviewed Sugerii’s IP, mapping the global technological and patent landscape. This included a detailed comparative analysis between Shurui SP and more than 3,000 valid, granted patents held by leading endoscopic surgical robot companies across Europe and the U.S.
Surgerii said the analysis found that, despite the highly dense patent landscape, its robot “has achieved disruptive innovation and breakthroughs in key technologies.” The company asserted that its approach is significantly distinguished from existing surgical patents, providing a solid technological and legal foundation to operate and commercialize Shurui in international markets.
Shurui approved for adult, pediatric patients
The SR-ENS-600 obtained marketing approval from China’s National Medical Products Administration (NMPA) in June 2023. Surgerii said Shurui SP was first single-port endoscopic surgical robot to gain such approval in China.
In August 2025, the robot received CE certification, enabling its use across urology, gynecology, general surgery, and thoracic surgery for both adult and pediatric patients. Surgerii claimed it is the only CE-certified single-port surgical robot approved for pediatric use and the first Chinese surgical robot to be certified for the use in patients of all age group.
To date, the company has established clinical cooperation with over 70 Grade A tertiary hospitals in China, performed more than 3,000 surgeries, been involved in nearly 50 procedures worldwide, and developed over 80 surgical techniques that fill gaps in clinical practice across Asia or China. These procedures range from pancreaticoduodenectomy for pancreatic cancer to surgeries on pediatric patients as young as 7 days old.
Surgerii said it has demonstrated that its technology can reduce surgical trauma while covering an even broader patient population than multi-port surgical robots. Shurui does not yet have U.S. Food and Drug Administration approval.
Investment to boost European adoption
Loyal Valley Capital, a private equity firm focusing on healthcare and technology innovations, led Surgerii Robotics’ Series round.
Other participants included Shanghai Healthcare Capital, a strategic investor in healthcare segment leaders; V Star Capital and DNV Capital, both specializing in healthcare innovations; and Hefei Industrial Investment, an investor with extensive experience and industrial resources in hard technology and strategic emerging industries.
Surgerii noted that this investment came as it is deepening its domestic market penetration and accelerating international commercialization.
“Leveraging the strong support from this new round financing, the company will further the clinical adoption, develop advanced energy instruments, thereby deepening the therapeutic value of single-port robots in more and complex cases, as well as creating a disruptive systematic solution centered on cutting-edge technology to benefit a wider range of patients,” it stated.
In 2025, Surgerii established the European Clinical Excellence Center in collaboration with IRCAD, a leading institution for minimally invasive surgical training. The company added that it has set its strategic focus on the high-end European market.
